United States Pharmaceuticals and Healthcare Report Q2 2008 : Market Research Report

United States Pharmaceuticals and Healthcare Report Q2 2008

Published by: Business Monitor International

Published: May. 16, 2008 - 110 Pages

Executive Summary: US Pharmaceuticals And Healthcare Industry SWOT; United States Political SWOT; United States Economic SWOT; US Pharmaceutical Business Environment Ratings; Table: Americas Pharmaceutical Business Environment Rankings; Limits To Potential Returns; United States - Market Summary; Regulatory Regime; Intellectual Property Developments; Pricing And Reimbursement Issues; Industry Developments; Healthcare Sector; Universal Healthcare; Table: US Health Insurance Key States,05; Part D; Democrats Controlling Congress; Biotechnology Sector; Table: Biotechnology Medicines Under Development,06; Table: Top 10 Biotech IPOs,06; Statins; Advertising Sector; Product Approvals; Merck Settles Over Vioxx; Mergers And Acquisitions; Marketing Sector; Research And Development Sector; Generics Sector; Wal-Mart Enters The Fray; Authorised Generics; Biogenerics; Canadian Imports; Pharmacy Sector; Manufacturing Sector; Vaccine-preventable Diseases; Industry Forecast Scenario; Overall Market Forecast; Table: US Pharmaceuticals And Healthcare Sector - Historical Data And Forecasts; Key Growth Factors - Industry; Key Growth Factors - Macroeconomic; Table: United States - Macroeconomic Forecasts; Patented Market Forecast; Table: Patented Market Indicators; OTC Market Forecast; Table: OTC Market Indicators (US$mn unless otherwise stated); Generics Market Forecast; Table: Generics And Patented Market Indicators; Export/Import Forecasts; Table: US Pharmaceuticals And Healthcare Sector (US$mn); Other Healthcare Data; Table: US Pharmaceuticals And Healthcare Sector; Table: US Pharmaceuticals And Healthcare Sector; Competitive Landscape.77; Overview; Market Data; Table: Leading 10 Therapeutic Classes By US Sales,06. 78; Table: Leading 10 Products By US Sales,06; Table: 10 Leading Corporations By US Sales,06; Table: 10 Leading Corporations By Total US Dispensed Prescriptions,06; Table: Channel Distribution By US Dispensed Prescription,06; Table: Channel Distribution By US Sales,06; Table: Leading 10 Products By Total US Dispensed Prescriptions,06; Table: HMG-COA Reductase Inhibitors (statins) - Total US Sales (US$’000); Table: Proton Pump Inhibitors - Total US Sales (US$’000); Table: Antidepressants (includes SSRI, SNRI and newer generation) - Total US Sales (US$’000); Table: Antiarthitics, COX-2 Inhibitors - Total US Sales (US$’000); Table: Sexual Function Disorder - Total US Sales (US$’000); Company Profiles; Pfizer; GlaxoSmithKline (GSK); Novartis; Merck & Co; Eli Lilly; Bristol-Myers Squibb (BMS); Amgen; Genentech; BMI Forecast Modellin106; How We Generate Our Industry Forecasts; Pharmaceutical Industry; Pharmaceutical Business Environment Ratings Methodology; Ratings Overview; Table: Pharmaceutical Business Environment Indicators; Sources

Abstract

Despite concerns over the economy, the US drug market should continue its solid growth in the comingyears with BMI expecting a compound annual growth rate (CAGR) of 3.99% for 2007-2012. By the endof the forecast period total drug expenditure should reach US$364.7bn.

The key driver of growth is swelling health expenditure, which in the next five years should breach the US$3trn mark. According to data from the OECD, in 1980 the US spent 8.8% of GDP on health. In 2012, BMI estimates that this will have risen to 17.9%, by far the highest level in the world. The event that willhave the most impact on health expenditure will be the Presidential election in 2008. The two leading Democratic candidates - Barack Obama and Hillary Clinton - have both pledged to implement universalhealth systems if elected. However, it is difficult to know whether this would have an inflationary ordeflationary impact. Less emphasis on the private sector might stop health insurance premiums spirallingupwards, but bringing more than 40mn uninsured citizens under coverage will also require increasedspending. Meanwhile, underlying trends such as the rapidly ageing population and increasing numbers ofretirees will continue unabated.

One problem that drugmakers are complaining about is raised approval standards at the US FDA, meaning that fewer product candidates are making the grade. Jean-Paul Garnier, CEO of Glaxo Smith Kline (GSK), claims that his company is preparing 25 launches over the next few years, but anumber are being delayed, which would not have been delayed two years ago. This has caused BMI toslightly downgrade the US’s Business Environment Ranking, although the country is still comfortably theleader in the Americas region and is still at the top of the global rankings ahead of Switzerland.Tougher operating conditions have not deterred FDI. Over the past quarter a number of US assets havebeen snapped up with OTC firm Adams Respiratory Therapeutics being bought by UK-based Reckitt Benckiser. Japanese drugmaker Astellas has also acquired US-based biotech firm Agensys in a dealworth US$537mn, as it looks to expand its portfolio of monoclonal antibody (MAb) therapies. The fallingdollar, meanwhile, has played into the hands of domestic drugmakers, such as Schering-Plough, with astrong presence overseas.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

United States Pharmaceuticals and Healthcare Report Q2 2008

Table of Contents

Abstract